Pharmacodynamic analysis of the electrocardiographic interaction between disopyramide and erythromycin in rats

Journal of Pharmaceutical Sciences

Volumn 88, Issue 2, 1999, Pages 234-240

  Hanada, Erika ^a   Ohtani, Hisakazu ^a   Kotaki, Hajime ^b   Sawada, Yasufumi ^c   Sato, Hitoshi ^a   Iga, Tatsuji ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DISOPYRAMIDE; ERYTHROMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG POTENTIATION; ELECTROCARDIOGRAM; NONHUMAN; PHARMACODYNAMICS; QT INTERVAL; RAT; TORSADE DES POINTES;

EID: 0032970827     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js980256r     Document Type: Article

References (41)

1. Ragosta, M.; Weihl, A. C.; Rosenfeld, L. E. Potentially fatal interaction between erythromycin and disopyramide. Am. J. Med. 1989, 86, 465-466.
2. Kawamoto, T.; Emoto, C.; Yoshino, T.; Maruyama, T.; Tamura, R.; Komuro, R.; Ishikawa, K. A case of torsade de pointes occurred by interaction between erythromycin and disopyramide. Shinzou 1993, 25(6), 696-701.
3. Karim, A. The pharmacokinetics of norpace. Angiology 1975, 26(S-1), 85-98
4. Periti, P.; Mazzei, T.; Mini, E.; Novelli, A. Pharmacokinetic drug interactions of macrolides. Clin. Pharmacokinet. 1992, 23(2), 106-131.
5. Echizen, H.; Kawasaki, H.; Chiba, K.; Tani, M.; Ishizaki, T. A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes. J. Pharmacol. Exp. Ther. 1993, 264(3), 1425-1431.
6. Brandriss, M. W.; Richardson, M. S.; Barold, S. S. Erythromycin-induced QT prolongation and polymorphic ventricular tachycardia (Torsades de Pointes): Case report and review. Clin. Infect. Dis. 1994, 18, 995-998.
7. Gitler, B.; Bergeer, L. S.; Buffa, S. D. Torsades de pointes induced by erythromycin. Chest 1994, 105(2), 368-372.
8. Orban, Z.; MacDonald, L. L.; Peters, M. A.; Guslits, B. Erythromycin-induced cardiac toxicity. Am. J. Cardiol. 1995, 75, 859-861.
9. Lin, J. C.; Quasny, H. A. QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine. Pharmacotherapy 1997, 17(3), 626-630.
10. Ohtani, H.; Hanada, E.; Yamamoto, K.; Sawada, Y.; Iga, T. Pharmacokinetic-pharmacodynamic analysis of the electrocardiographic effects of terfenadine and quinidine in rats. Biol. Pharm. Bull. 1996, 19(9), 1189-1196.
11. Mayer, F.; Kramer, B. K.; Res, K. M.; Kuhlkamp, V.; Liebich, H. M.; Risler, T.; Seipel, L. Simplified, rapid and inexpensive extraction procedure for a high-performance liquid chromatographic method for determination of disopyramide and its main metabolite mono-N-dealkylated disopyramide in serum. J. Chromatogr. 1991, 572, 339-345.
12. Hanada, E.; Ohtani, H.; Kotaki, H.; Sawada, Y.; Iga, T. Determination of erythromycin concentrations in rat plasma and liver by high-performance liquid chromatography with amperometric detection. J. Chromatogr. B 1997, 692, 478-482.
13. Wagner, J. G. Fundamentals of Clinical Pharmacokinetics; Intelligence Publication Ins.: Hamilton, Illinois, 1975; pp 90-102.
14. Holford. N. H. G.; Sheiner L. B. Undertanding the Dose-Effect Relationship; Clinical Application of Pharmacokinetic-Pharmacodynamic Models. Clin. Pharmacokinet. 1981, 6, 429-453.
15. Ito, T.; Takahashi, Y.; Tomidokoro, K.; Nishino, T.; Fukuzawa, Y.; Chiba, K.; Miyazaki, S.; Takada, M. The mechanism of the renal excretion of disopyramide in rats (I). Yakugaku Zasshi 1992, 112(5), 336-342.
16. Cook, C. S.; Karim, A.; Sollman, P. Stereoselectivity in the metabolism of disopyramide enantiomers in rat and dog. Drug Metab. Dispos. 1982, 10(2), 116-121
17. Hayes, E.; Pugsley, M. K.; Penz, W. P.; Adaikan, G.; Walker, M. J. A. Relationship between QaT and RR intervals in rats, guinea pigs, rabbits, and primates. J. Pharmacol. Toxicol. Med. 1994, 32(4), 201-207.
18. Keren, A.; Tzivoni, D.; Gavish, D.; Levi, J.; Gottlieb, S.; Benhorin, J.; Stern, S. Etiology, warning signs and therapy of torsade de pointes. A study of 10 patients. Circulation 1981, 64, 1167-1174.
19. Schanne, O. F.; Bkaily, G.; Dumais, B.; Boutin, L. Disopyramide phosphate effects on slow and depressed fast responses. Can. J. Physiol. Pharmacol. 1986, 64, 487-491.
20. Kus, T.; Sasyniuk, B. I. Electrophysiological actions of disopyramide phosphate on canine ventricular muscle and Purkinje fibers, Circulation Res. 1975, 37, 844-854.
21. Campbell, T. J. Kinetics of onset of rate-dependent effects of class I antiarrythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification. Cardiovasc. Res. 1983, 17, 344-352.
22. Hiraoka, M.; Kuga, K.; Kawano, S.; Sunami, A.; Fan, Z. New observations on the mechanisms of antiarrythmic actions of disopyramide on cardiac membranes. Am. J. Cardiol. 1989, 64, 15J-19J.
23. Vanhoutte, F.; Vereecke, J.; Carmeliet, E.; Verbeke, N. Effects of the enantiomers of disopyramide and its major metabolite on the electrophysiological characteristics of the guinea-pig papillary muscle. Naunyn-Schmiedeberg's Arch. Pharmacol. 1991, 344, 662-673.
24. Grant, A. M.; Marshall, R. J.; Ankier, S. I. Some effects of disopyramide and its N-dealkylated metabolite on isolated nerve and cardiac muscle. Eur. J. Pharmacol. 1978, 49, 389-394.
25. Boucher, M.; Chassaing, C.; Herbet, A.; Duchene-Marullas, P. Interactions with the cardiac cholinergic system: Effects of disopyramide and its mono-N-dealkylated metabolite. Life Sci. 1992, 50(20), PL161-166.
26. Bergfeldt, L.; Gustafsson, K. S.; Dahlqvist, R. Comparative class I electrophysiologic and anticholinergic effects of disopyramide and its main metabolite (mono-N-dealkylated disopyramide) in healthy humans. Cardiovasc. Drug. Ther. 1992, 6, 529-537.
27. Rubart, M.; Pressler, M. L.; Pride, H. P.; Zipes, D. P. Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome. Circulation 1993, 88(4), 1832-44.
28. Daleau, P.; Lessard, E.; Groleau, M.-F.; Turgeon, J. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation 1995, 91(12), 3010-16.
29. Antzelevitch, C.; Sun, Z.-Q.; Zhang, Z.-Q.; Yan, G.-X. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J. Am. Coll. Cardiol. 1996, 28(7), 1836-48.
30. Whiting, B.; Holford, N. H. G.; Sheiner, L. B. Quantitative analysis of the disopyramide concentration-effect relationship. Br. J. Clin. Pharmacol. 1980, 9, 67-75.
31. Coraboeuf, E.; Deroubaix, E.; Escande, D.; Coulombe, A. Comparative effects of three class I antiarryhythmic drugs on plateau and pacemaker currents of sheep cardiac Purkinje fibers. Cardiovasc. Res. 1988, 22, 375-384.
32. Lima, J. J.; Boudoulas, H.; Blanford, M. Concentrationdependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics. J. Pharmacol. Exp. Ther. 1981, 219(3), 741-747.
33. Karim, A.; Ranney, R. E.; Karaychy, S. Species differences in the biotransformation of a new antiarrhythmic agent: disopyramide phosphate. J. Pharmacothuet. Sci. 1972, 61(6), 888-893.
34. Corre, P.; Gibassier, D.; Sado, P.; Verge, R. L. Human pharmacokinetics and metabolism of disopyramide enantiomers. Eur. J. Drug Met., Pharmacokinet. 1991, 3, 233-237.
35. Echizen, H.; Mochizuki, K.; Tani, M.; Ishizaki, T. Interspecies Differences in Enantioselective Mono-N-Dealkylation of Disopyramide by Human and Mouse Liver Microsomes. J. Pharmacol. Exp. Ther. 1993, 268(3), 1518-1525.
36. Delaforge, M.; Jaouen, M.; Mansuy, D. The cytochrome P-450 metabolite complex derived from troleandomycin: properties in vitro and stability in vivo. Chem. Biol. Interact. 1984, 15, 371-376.
37. Piscitelli, D. A.; Fisher, J. H.; Schoen, M, D.; Hoon, T. J.; Bauman, J. L. Bioavailability of total and unbound disopyramide: implications for clinical use of the immediate and controlled-release dosage forms. J. Clin. Pharmacol. 1994, 34, 823-828.
38. Sadanaga, T.; Ogawa, S.; Okada, Y.; Tsutsumi, N.; Iwanaga, S.; Yoshikawa, T.; Akaishi, M.; Handa, A. Clinical evaluation of the use-dependent QRS prolongation and the reverse usedependent QT prolongation of class I and class III antiarrythmis agents and their value in predicting efficacy. Am. Heart J. 1993, 126(1), 114-121.
39. Longmore, J.; Berry, J. L.; Szabadi, E.; Bradshaw, C. M. A comparison of the anticholinergic effects of two formulations of disopyramide in healthy volunteers. Eur. J. Clin. Pharmacol. 1990, 39, 305-309.
40. Endresen, K.; Amlie, J. P.; Forfang, K. Effects of disopyramide on repolarization and intraventricular conduction in man. Eur. J. Clin. Pharmacol. 1988, 35, 467-474.
41. Freedman, R. A.; Anderson, K. P.; Green, L. S.; Mason, J. W. Effect of erythrpmycin on ventricular arrhythmias and ventricular repolarization in idiopathic long QT syndrome. Am. J. Cardiol. 1987, 59, 168-169.